Ultralow-Dose IL 10–Expressing CAR T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Дата публикации: 23-07-2026 00:00:00

This nonrandomized clinical trial examines the safety and efficacy of interleukin-10–expressing CD19 chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	CAR T-терапия показала успешные результаты у пациентов с резистентной лимфомой	0	12.63	14-10-2026
2	Prognostic factors and an exploratory risk stratification model in newly diagnosed Pola-R-CHP-treated diffuse large B-cell lymphoma: A real-world retrospective cohort analysis	0	23.54	20-08-2026
3	Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory iNHL and CLL	0	2.16	27-08-2026
4	Immune Checkpoint Inhibitor–Based Downstaging Therapy for Hepatocellular Carcinoma	0	7.13	01-10-2026
5	Immune Checkpoint Inhibitors for Child-Pugh B Hepatocellular Carcinoma	0	11.22	01-10-2023
6	Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors	0	5.21	27-08-2026
7	Sanidad financia una nueva opción de tratamiento para pacientes con un subtipo de linfoma agresivo	0	6.7	02-10-2026
8	Mejoran la respuesta a un tratamiento clave en un tipo agresivo de linfoma	0	8.52	15-04-2026
9	Ученые сообщили о результатах CAR-T-терапии при трудноизлечимой миеломе	0	18.33	25-09-2026
10	NAVITOCLAX (ABT-263) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE/RITUXIMAB (FCR) OR BENDAMUSTINE/RITUXIMAB (BR): A PHASE 1 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	0	5	27-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 14.62. Источник: jamanetwork.com.